

antibodies were detected with green fluorescence (Fig. 4B; left panel), and the anti-IL-17 primary antibodies were detected with red fluorescence (Fig. 4B; middle panel). A merged image of the two fluorophores, displayed in yellow, shows that most of the CD4⁺ cells in tumor tissues are stained with anti-IL-17 antibody (Fig. 4B; right panel). Therefore, Th17 cells that infiltrate tumor tissues produced IL-17.

IL-17 mRNA expression and clinicopathological characteristics. To evaluate the biological significance of IL-17 expression in tumor tissues in patients with gastric cancer, we investigated the association of mRNA expression levels of IL-17 with clinicopathological factors (Table I). IL-17 mRNA expression levels in gastric tumors were higher in positive groups of venous invasion, lymphatic invasion and lymph node metastases than in negative groups. IL-17 mRNA expression levels in gastric tumors increased according to the depth of invasion and the stage of disease. On the other hand, no significant association was recognized between the expression levels of IL-17 mRNA and histological type and tumor size.

Discussion

In this study, we quantitatively analyzed the expression of IL-17 mRNA in gastric tumor tissues. IL-17 was originally identified as a proinflammatory cytokine that induces neutrophils (4) and previous studies also have shown that inflammation is linked to cancer development and progression. Therefore, it is reasonable to speculate that proinflammatory Th17 cells may accumulate and produce IL-17 in the tumor microenvironment. Indeed, we showed in the present study that the expression level of IL-17 mRNA in tumor tissues was significantly higher compared with that in adjacent normal tissues. In addition, we examined IL-17 expression in tumor and normal tissues by immunohistochemistry, and showed that, in contrast to normal glands, malignant glands were surrounded by dense inflammatory cells including many IL-17-producing cells. This result was consistent with the data of IL-17 mRNA expression. Conventionally, it has been reported that IL-17 is predominantly produced by CD4⁺ helper T cells, which have been termed 'Th17' (5). However, recent studies have shown that T cells other than CD4⁺ T cells, such as $\gamma\delta$ T cells and CD8⁺ T cells, produce IL-17 in mouse models (23,24). In the present study, we performed double immunofluorescence histochemistry using anti-IL-17 and CD4 antibodies in tumor tissues to identify IL-17-producing cells in human gastric cancer tissues. We showed that most of the CD4⁺ cells infiltrating tumors were also stained with anti-IL-17 antibody, suggesting that IL-17 was predominantly produced by conventional Th17 cells in human gastric cancer tissues. Consistent with this observation, it has been reported that there is a high percentage of Th17 cells in tumor-derived T cell populations in 5 of 10 ovarian tumors, and those Th17 cells secreted IL-17 (17).

Differentiation of Th17 cells from naïve T cells is dependent on signals from TGF- β , IL-6, IL-21 and IL-23 in mice (21). Importantly, IL-21 is essential for the generation of Th17 cells and also amplifies Th17 cell differentiation (20). IL-23 does not act on naïve T cells, but instead acts on T cells that

are already committed to the Th17 lineage. IL-23 enhances the production of IL-17 and stabilizes the Th17 phenotype (25,26). In humans, IL-21 likewise is required for differentiation of Th17 cells, and IL-23 enhances IL-17 secretion from those cells (27,28). However, there have been few studies to investigate the expression of IL-17-related cytokines such as IL-21 and IL-23, which play a crucial role in the generation of Th17 cells and the production of IL-17 in the tumor tissues of cancer patients. Our data showed that mRNA expression of both IL-21 and IL-23 was higher in gastric tumor tissues than in non-cancerous adjacent tissues. Importantly, in tumor tissues, the IL-21 mRNA expression level showed a strong correlation with the IL-17 mRNA expression level, but the IL-23 mRNA expression level did not show as strong a correlation with the IL-17 mRNA expression level. We also examined other cytokines such as TGF- β and IL-6, but we did not find a correlation as strong as that of IL-17 with IL-21 (data not shown). In addition, we performed immunohistochemical staining for IL-21 in tumor tissues and non-cancerous adjacent tissues to identify IL-21-producing cells. As with IL-17, there were many IL-21-positive cells around malignant glands, although the IL-21-positive cells did not always coincide with the IL-17-positive cells (Fig. 5). These results suggest that IL-21 may be crucial for the generation of Th17 cells and may play a pivotal role in the regulation of IL-17 secretion in the tumor microenvironment.

IL-17 is expressed in a considerable proportion of patients with ovarian cancer and its expression is associated with tumor angiogenesis (14). IL-17 up-regulates production of a variety of proangiogenic factors, such as vascular endothelial growth factor (VEGF), prostaglandin E1 (PGE1) and PGE2, and macrophage inflammatory protein-2 (MIP-2), by fibroblasts as well as tumor cells; IL-17 also promotes angiogenesis through stimulation of vascular endothelial cell migration and cord formation, resulting in tumor progression (11). The microvessel density and other angiogenic factors such as VEGF and PGE1, which are related to tumor development and progression, are predictive of patient survival in patients with gastric cancer. Therefore, it is important to examine the association of the expression level of IL-17 mRNA and angiogenesis in tumor tissues for the purpose of clarifying the biological significance of IL-17 in the tumor microenvironment. Our results revealed that tumor tissues with high expression levels of IL-17 mRNA had significantly higher microvessel density than those with low expression levels. Our findings strongly suggested that IL-17 released from tumor-infiltrating Th17 cells promoted angiogenesis by the production of proangiogenic chemokines in human gastric cancer. That process may lead to tumor progression.

From the standpoint of inflammation, IL-17 has the ability to stimulate IL-8 production in both epithelial cells and macrophages raising the possibility that this cytokine may play an important role in the recruitment of inflammatory cells in the tumor microenvironment. Neutrophils, acting alone or in concert with macrophages, also have been linked to tumor progression (2). Tumor-associated neutrophils promote tumor progression by a variety of mechanisms, including stimulation of angiogenesis and invasion (29). It has been shown in several tumor transplant models that tumor-associated neutrophils can stimulate tumor angiogenesis through production of

proangiogenic factors, including VEGF, IL-8 and certain proteases such as matrix metalloproteinases and elastases, and that these neutrophils can facilitate tumor progression. In this study, immunostaining for neutrophils revealed that tumor tissues with high expression levels of IL-17 mRNA had more infiltrating neutrophils than tissues with low expression levels. This observation suggested that IL-17 from Th17 recruited neutrophils into the tumor microenvironment, and that these tumor-associated neutrophils may contribute to the invasive potential.

There are conflicting data on a possible role in carcinogenesis in mouse models. Forced overexpression of IL-17 ectopically in tumor cells can either suppress tumor progression through enhanced antitumor immunity (12,30) or promote it through an increase in inflammation and angiogenesis (11). The role of endogenous IL-17 in tumorigenesis has been assessed with IL-17 knockout mice (13). Although the results are still controversial, they give useful information for clarifying whether IL-17 promotes or inhibits tumor progression in human cancer and for investigating the association of locally expressed IL-17 and clinicopathological characteristics in patients with gastric cancer. In this study, we focused on the clinical significance of IL-17 in the tumor microenvironment. To our knowledge, no prior reports exist on the correlations between locally expressed IL-17 and clinicopathological factors of cancer patients from this point of view. Although Zhang *et al* reported that IL-17 was significantly increased in serum and tumor-draining lymph nodes in patients with advanced gastric cancer (16), locally expressed IL-17 would have quite a different role in tumor progression. This study is the first to report the clinical significance of locally expressed IL-17 in gastric cancer. Clinicopathological analysis revealed that patients with high IL-17 mRNA expression level showed a deeper invasion of tumors into the wall, more lymph-vascular invasion and more positive lymph node involvement than those with low expression. IL-17 at the tumor sites may thus play a vital role in proliferation and progression of gastric cancer.

In conclusion, our findings showed that CD4⁺ Th17 cells were generated around the tumor, and that Th17 cells infiltrated the tumor and secreted IL-17, leading to tumor progression through angiogenesis and neutrophil infiltration in patients with gastric cancer. One of the key cytokines to regulate the production of IL-17 in the tumor microenvironment was thought to be IL-21. It was suggested that IL-17 or IL-21 locally expressed in the tumor would be a potential therapeutic target for treatment of patients with advanced gastric cancer.

References

- Hussain SP and Harris CC: Inflammation and cancer: an ancient link with novel potentials. *Int J Cancer* 121: 2373-2380, 2007.
- Coussens LM and Werb Z: Inflammation and cancer. *Nature* 420: 860-867, 2002.
- Craanen ME, Blok P, Dekker W and Tytgat GNJ: *Helicobacter pylori* and early gastric cancer. *Gut* 35: 1372-1374, 1994.
- Fossiez F, Djossou O, Chomarat P, *et al*: T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. *J Exp Med* 183: 2593-2603, 1996.
- Yao Z, Fanslow WC, Seldin MF, *et al*: Herpesvirus saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. *Immunity* 3: 811-821, 1995.
- Chabaud M, Fossiez F, Taupin JL and Miossec P: Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. *J Immunol* 161: 409-414, 1998.
- Steinman L: A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. *Nat Med* 13: 139-145, 2007.
- Shahrara S, Huang Q, Mandelin AM II and Pope RM: TH-17 cells in rheumatoid arthritis. *Arthritis Res Ther* 10: R93, 2008.
- Fina D, Sarra M, Fantini MC, *et al*: Regulation of gut inflammation and Th17 cell response by interleukin-21. *Gastroenterology* 134: 1038-1048, 2008.
- Luzza F, Parrello T, Monteleone G, *et al*: Up-regulation of IL-17 is associated with bioactive IL-8 expression in *Helicobacter pylori*-infected human gastric mucosa. *J Immunol* 165: 5332-5337, 2000.
- Numasaki M, Fukushi J, Ono M, *et al*: Interleukin-17 promotes angiogenesis and tumor growth. *Blood* 101: 2620-2627, 2003.
- Benchetrit F, Ciree A, Vives V, *et al*: Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. *Blood* 99: 2114-2121, 2002.
- Kryczek I, Wei S, Szeliga W, Vatan L and Zou W: Endogenous IL-17 contributes to reduced tumor growth and metastasis. *Blood* 114: 357-359, 2009.
- Kato T, Furumoto H, Ogura T, *et al*: Expression of IL-17 mRNA in ovarian cancer. *Biochem Biophys Res Commun* 282: 735-738, 2001.
- Langowski JL, Zhang X, Wu L, *et al*: IL-23 promotes tumour incidence and growth. *Nature* 442: 461-465, 2006.
- Zhang B, Rong G, Wei H, *et al*: The prevalence of Th17 cells in patients with gastric cancer. *Biochem Biophys Res Commun* 374: 533-537, 2008.
- Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J and Wang RF: Generation and regulation of human CD4⁺ IL-17-producing T cells in ovarian cancer. *Proc Natl Acad Sci USA* 105: 15505-15510, 2008.
- McGeachy MJ, Bak-Jensen KS, Chen Y, *et al*: TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. *Nat Immunol* 8: 1390-1397, 2007.
- Sergio R: Human Th17 cells. *Arthritis Res Ther* 10: 206, 2008.
- Nurieva R, Yang XO, Martinez G, *et al*: Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. *Nature* 448: 480-483, 2007.
- McGeachy MJ and Cua DJ: Th17 cell differentiation: the long and winding road. *Immunity* 28: 445-453, 2008.
- Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. *N Engl J Med* 324: 1-8, 1991.
- O'Brien RL, Roark CL and Born WK: IL-17-producing gamma delta T cells. *Eur J Immunol* 39: 662-666, 2009.
- Nam JS, Terabe M, Kang MJ, *et al*: Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. *Cancer Res* 68: 3915-3923, 2008.
- Betelli E, Korn T, Oukka M and Kuchroo VK: Induction and effector functions of T(H)17 cells. *Nature* 453: 1051-1057, 2008.
- Miossec P, Korn T and Kuchroo VK: Interleukin-17 and type 17 helper T cells. *N Engl J Med* 361: 888-898, 2009.
- Yang L, Anderson DE, Baecher-Allan C, *et al*: IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. *Nature* 454: 350-352, 2008.
- Hoeve MA, Savage ND, de Boer T, *et al*: Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. *Eur J Immunol* 36: 661-670, 2006.
- Benelli R, Albini A and Noonan D: Neutrophils and angiogenesis: potential initiators of the angiogenic cascade. *Chem Immunol Allergy* 83: 167-181, 2003.
- Hirahara N, Nio Y, Sasaki S, *et al*: Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. *Oncology* 61: 79-89, 2001.

Comparison of different classes of CpG-ODN in augmenting the generation of human epitope peptide-specific CTLs

MASAHIRO KATSUDA, MAKOTO IWAHASHI, KENJI MATSUDA, MOTOKI MIYAZAWA, MIKIHITO NAKAMORI, MASAKI NAKAMURA, TOSHIYASU OJIMA, TAKESHI IIDA, KEIJI HAYATA and HIROKI YAMAUE

Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan

Received January 10, 2011; Accepted March 28, 2011

DOI: 10.3892/ijo.2011.1146

Abstract. Three distinct classes of CpG-oligonucleotides (ODN) (CpG-A, CpG-B and CpG-C) have been identified on the basis of differences in their structures and immune effects. To date, only CpG-B is applied for clinical treatments; however, it is still unknown which of the different CpG-ODN classes is most useful as an adjuvant for human cancer vaccine therapy. In the present study, we examined the activity of these 3 types of CpG-ODN in enhancing the induction of human peptide-specific CTLs. Our data showed that the specific cytotoxicity was augmented in the presence of CpG-A, -B and -C but not in the presence of control ODN, and the augmenting effect was most potent with CpG-A. Flow cytometric analysis showed the subpopulation of effector-memory cells in CD8⁺ cells was most increased with CpG-A. Furthermore, depletion of PDCs from PBMCs before stimulation with peptide and CpG-ODN completely abrogated the augmenting effect of CpG-ODN. These data indicated that the stimulation of PDCs by CpG-ODN augmented the generation of peptide-specific CTLs, and CpG-A was superior to CpG-B and CpG-C in terms of augmenting the generation of human peptide-specific CTLs *in vitro*.

Introduction

The innate immune system is activated via exposure to pathogen-associated molecular patterns (PAMPs) that are expressed by a diverse group of infectious microorganisms. Subsequently, the host mounts an adaptive immune response directed against determinants that are uniquely expressed by the pathogen. The resultant antigen-specific immunity is characterized by the production of high-affinity antibodies and the generation of cytotoxic T cells that provide long-lasting protection (1).

The key feature of innate immune cells that enables them to detect and categorize infection seems to be their repertoire of what have been termed pattern-recognition receptors (PRRs). The best understood family of PRRs is the toll-like receptors (TLRs), of which 10 are known in humans.

In contrast to viruses and other pathogens, vaccines containing recombinant proteins or synthetic antigenic peptides usually fail to induce significant immune responses unless they are mixed with adjuvant (3,4). Because of their high efficacy, several recently identified TLR ligands are promising vaccine adjuvants. Bacterial unmethylated CpG-rich oligodeoxy-nucleotides (ODN), which bind to TLR-9, are one of the most promising candidates for a cancer vaccine adjuvant and are currently being tested in many human clinical trials (5-8).

In numerous murine models, TLR-9 activation enhances antigen-specific cellular responses to a wide variety of antigens. The mechanism that contributes to the potent adjuvant activity of CpG-ODNs is maturation and differentiation of dendritic cells resulting in the strong induction of CTLs, even in the absence of CD4 T-cell help (9). On the other hand, the cellular patterns of TLR expression vary between different species (2,10). B cells, monocytes and all DC subsets express TLR-9 in mice; however, only plasmacytoid dendritic cells (PDC) and B cells express TLR-9 in humans (11-14). Consequently, the murine immune system produces different actions from human systems when exposed to CpG-ODN. Therefore, it is impossible to extrapolate the experimental results from murine models to humans. Furthermore, little is known about the mechanism by which CpG-ODNs augment acquired cellular immunity in humans, although systemically administered CpG-ODNs have shown substantial evidence of augmenting the activity of anti-tumor immunity in human clinical cancer vaccine trials (5-8).

Three distinct classes of CpG-ODN have been identified on the basis of differences in their structures and immune-stimulating effects (9,15-17). CpG-A induces the production of high levels of IFN- α from PDC with relatively little B-cell stimulation. In contrast, CpG-B induces the production of low levels of IFN- α along with profound B-cell activation. CpG-C has intermediate immune effects with excellent *in vivo* stability and ease of formation. To date, only CpG-B has been applied for clinical treatments; however, the class of CpG-ODN

Correspondence to: Dr Makoto Iwahashi, Second Department of Surgery, School of Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-8510, Japan
E-mail: makoto@wakayama-med.ac.jp

Key words: CpG-ODN, peptide vaccine, effector-memory cells

that is most useful as an adjuvant for a human cancer vaccine is still unknown.

In the present study, we examined the immuno-modulatory activity of these 3 types of CpG ODN in terms of the generation of peptide-specific CTLs.

Materials and methods

Cell lines. A24+LCL cells (HLA-A24/24) were a generous gift of Takara Shuzo Co., Ltd. (Otsu, Japan). The A24LCL cells were used for peptide-mediated cytotoxicity assays. These cells were maintained in a tissue culture flask using RPMI and supplemented with antibiotics and 10% heat-inactivated fetal calf serum (Gibco BRL).

Oligodeoxynucleotides. CpG-A was synthesized by Gene Design (Osaka, Japan). CpG-B, CpG-C and GpC-ODN were synthesized by Hokkaido System Science (Sapporo, Japan); CpG-A, 5'-ggTGCATCGATGCAGGGGgg-3'; CpG-B, 5'-tcgtcgttttgcgttttgcgtt-3'; CpG-C, 5'-tcgtcgaacgttcagagatgat-3'; GpC-ODN, the GC control to CpG-ODN, 5'-ggTGCATGCATGCAGGGGgg-3' (lower case letters indicate phosphorothioate linkage; capital letters, phosphodiester linkage 3' of the base; bold, CpG-dinucleotides).

Peptides. Peptide derived from the squamous cell carcinoma-associated differentiation antigen LY6K-177 (RYCNLEGPPI), influenza (flu) virus-derived peptide (RFYIQMCYEL) and HIV-derived peptide (RYLRDQQLL) with the HLA-A24 binding motif were purchased from Takara Bio Inc. (Otsu, Japan). The purity (>90%) and the identity of the peptides were determined by analytical HPLC and mass spectrometry analysis, respectively. Peptides were dissolved in dimethyl-sulfoxide (DMSO) at 20 mg/ml and stored at -80°C.

Cytokine assays. Human PBMCs from healthy volunteers (n=15) were isolated from freshly drawn peripheral blood by Ficoll-Hypaque (Biochrom, Berlin, Germany) density gradient centrifugation. Blood donors were negative for HIV, hepatitis B virus (HBV) and HCV infection.

Freshly isolated PBMC (1x10⁶ in 500 µl of AIM-V media, Invitrogen) were incubated at 37°C with 5% CO₂ in 48-well flat-bottom plates with each class of CpG-ODN at different concentrations. Cell supernatants collected after 48 h were stored at -80°C until assayed. IFN-α in cell supernatants was measured by ELISA according to the manufacturer's instructions (PBL Biomedical Laboratories, Piscataway, USA). All assays were performed in triplicate.

Induction of flu peptide-specific CTLs. For this study, HLA-A24-positive donors were selected. PBMCs (2x10⁶/ml) isolated from healthy volunteers were stimulated with the flu peptide at a concentration of 10 µg/ml in the presence of CpG-ODNs (20, 5 and 5 µg/ml for CpG-A, -B and -C, respectively) in 24-well culture plates in AIM-V containing 2% heat-inactivated autologous serum (AS). In some experiments, PBMCs were depleted of PDCs using BDCA4-coupled magnetic beads (Miltenyi Biotec) according to the manufacturer's protocol (<0.01% PDCs identified as BDCA2⁺ and CD123⁺ after depletion) to investigate the role of PDCs on the adjuvant effect of

CpG-ODNs. On day 7, the T cells were further stimulated with the peptide-pulsed adherent cells that were cultured with autologous irradiated PBMCs for 4 h. The cytotoxic activity of CTLs was tested against peptide-pulsed A24-LCL cells on day 14 as indicated.

Induction of LY6K peptide-specific CTLs. Monocyte-derived dendritic cells (DCs) were used as antigen-presenting cells to induce CTLs against peptides presented on HLA. DCs were generated *in vitro* as previously described (18). Briefly, PBMCs isolated from healthy volunteers (HLA-A*2402) were separated by adherence to a plastic tissue culture dish (Becton-Dickinson) so as to enrich them for the monocyte fraction. The monocyte-enriched population was cultured in the presence of 1,000 U/ml GM-CSF (Kirin) and 500 U/ml IL-4 (Ono) in AIM-V containing 2% heat-inactivated AS. After 5 days in the culture, TNF-α (10 ng/ml), IL-6 (1,000 U/ml), IL-1β (10 ng/ml) and PGE2 (1 µg/ml) were added to the culture to mature DCs. After 7 days, DCs were pulsed with 20 µg/ml of the synthesized peptides in the presence of 3 µg/ml β2-microglobulin (Sigma), pulsed on the cytokine-generated DCs for 4 h at 37°C in AIM-V. These peptide-pulsed DCs were then inactivated by γ irradiation (50 Gy) and used as stimulator cells. To increase the precursor frequency of peptide-specific cells, CD8⁺ T cells were enriched by one round of positive selection using anti-CD8 antibody beads and MACS technology according to the manufacturer's protocol (Miltenyi Biotec; Bergisch-Gladbach, Germany). Then, CD8⁺ T cells and unseparated PBMCs were mixed at a 1:2 ratio and used as the responder cells. These cultures were set up in 48-well plates (Corning); each well contained 5x10⁴ stimulator cells and 1.5x10⁶ responder cells in the presence of CpG-ODNs in 0.5 ml of AIM-V/2% AS. In some experiments, PBMCs were depleted of PDCs using BDCA4-coupled magnetic beads (Miltenyi Biotec) according to the manufacturer's protocol. Two days later, these cultures were supplemented with IL-2 to a final concentration of 20 IU/ml. On day 7, the T cells were further re-stimulated with the autologous peptide-pulsed DCs. The peptide-pulsed DCs were prepared in the same manner as described above. CTL activity was tested against peptide-pulsed A24-LCL cells on day 14 as indicated.

Cytotoxicity assay. Target cells were labeled with 100 µCi of Na₂⁵¹CrO₄ (Perkin-Elmer Life Sciences) for 1 h at 37°C in a CO₂ incubator. Peptide-pulsed targets were prepared by incubating the cells with 20 µg/ml of the peptide for 16 h at 37°C before labeling. Labeled target cells were rinsed and mixed with effector cells in a final volume of 0.2 ml in round-bottom microtiter plates. The plates were centrifuged (4 min at 800 x g) to increase cell-to-cell contact and placed in a CO₂ incubator at 37°C. After 4 h of incubation, 0.1 ml of the supernatant was collected from each well and the radioactivity was determined with a γ counter. The percentage of specific cytotoxicity was determined by calculating the percentage of ⁵¹Cr release in 4 h using the following formula: [(cpm of the test sample release - cpm of the spontaneous release)/(cpm of the maximum release - cpm of the spontaneous release)] x 100. Spontaneous release was determined by incubating the target cells alone, in the absence of effector cells, and the maximum release was obtained by incubating the targets with 1 N HCl. All measurements were carried out in triplicate and the standard




Figure 1. IFN- α secretion from PBMCs stimulated by CpG-ODNs. Levels of IFN- α secreted by PBMC from healthy donors (n=15) after 48-h culture with media, GpC control ODN, A-Class, B-Class or C-Class CpG (all ODN at 0, 1, 5, 20, 80 μ g/ml). Bars show mean values and standard error of the means for each group of subjects.

errors of the means were consistently below 10% of the value of the mean.

Flow cytometric immunofluorescence analysis. Monoclonal antibodies against human CD8PerCP, CD45RAFITC and CCR7PE were purchased from BD Biosciences Pharmingen (Franklin Lakes, NJ, USA). Cells were incubated with specific antibodies in PBS for 30 min at 4°C, then analyzed using a FACSCalibur with the Cell Quest software package (Becton-Dickinson).

Results

IFN- α secretion from PBMCs stimulated by CpG-ODNs. Distinct ODN classes were studied for their ability to stimulate human PBMCs to secrete IFN- α . Consistent with previous reports (15-17), IFN- α secretion from PBMCs was greatest with CpG-A, and it was moderate with CpG-C; it was lowest with CpG-B. The dosages of CPG-A, B and C that induced the maximum level of IFN- α were 20, 5 and 5 μ g/ml, respectively (Fig. 1).

The effect of CpG-ODNs on the induction of the influenza peptide-specific CTL. The flu peptide-specific CTLs showed clear cytotoxicity against flu peptide-pulsed A24+LCL but not against HIV peptide-pulsed A24+LCL (Fig. 2A and B). The cytotoxicity against flu peptide-pulsed A24+LCL was

augmented in the presence of CpG-A, -B and -C but not in the presence of control ODN, and the augmenting effect was greatest with CpG-A; it was moderate with CpG-C and low with CpG-B (Fig. 2A). The depletion of PDCs from PBMCs before stimulation with peptide and CpG-ODNs completely abrogated the augmenting effect of each class of CpG-ODN (Fig. 2C-E). These data indicated that the stimulation of PDCs by CpG-ODNs augmented the expansion and activation of flu peptide-specific CTL to increase the specific cytotoxicity.

Flow cytometric analysis showed the population of CD8⁺ cells in flu peptide-specific CTLs. Interestingly, the subpopulation of effector-memory cells in CD8⁺ cells was most increased with CpG-A, and moderately increased with CpG-C (Fig. 3).

CpG-A augmented the LY6K peptide-specific CTL induction in a PDC-dependent manner. The population of LY6K peptide-specific CTL precursor cells in healthy volunteers may be much smaller than that of flu peptide-specific CTLs because LY6K is a cancer-testis antigen (19). Therefore, we investigated whether CpG-ODNs could also affect the induction of LY6K-specific CTLs. Although the induction of influenza-specific CTL was augmented by all types of CpG-ODN (Fig. 2A), the LY6K peptide-specific CTLs were induced only with CpG-A from both donors 1 and 2, but not with CpG-B or CpG-C (Fig. 4A-D). Depletion of PDCs from PBMCs of donor 2 before stimulation with peptide and CpG-A completely abrogated the effect of CpG-A (Fig. 4E).




Figure 2. CpG-ODNs augments the influenza peptide-specific CTL induction in a PDC-dependent manner. PBMCs from HLA-A24-positive healthy volunteers were stimulated with the flu peptide in the presence or absence of each class of CpG-ODN (20, 5 and 5 $\mu\text{g}/\text{ml}$ for CpG-A, -B and -C, respectively). After 7 days, effector cells were harvested and re-stimulated with the flu peptide pulsed on adherent cells of irradiated PBMCs. After another 7 days, the cytotoxicity of harvested cells against the HLA-A24-positive LCL-A24 cell line pulsed with the flu peptide (A) or a control HIV peptide (B) was assessed by standard ^{51}Cr release assay. Data shown are representative of three independent experiments. PDCs were depleted from PBMCs on day 0. After stimulation with peptide and CpG-ODNs, harvested cells were assessed by standard ^{51}Cr release assay in the same way (C-E).

These data indicated that the stimulation of PDCs by CpG-A augmented the expansion and activation of LY6K peptide-specific CD8^+ T cells.

Discussion

Recently, dozens of clinical trials of vaccine therapy for infectious diseases or cancers using CpG-ODNs as an adjuvant have been performed, and some of these trials have shown

promising results (5-8). In contrast, there have been few studies that showed the augmenting effects of CpG-ODNs on acquired immunity as a vaccine adjuvant (20). Therefore, the mechanism by which CpG-ODNs augment the efficiency of a vaccine has yet to be clarified in sufficient detail.

In the present study, the efficiency of *in vitro* flu peptide-specific CTL induction by flu peptide was enhanced in the presence of each type of CpG-ODN, and CpG-A showed a more potent adjuvant effect than CpG-B and CpG-C. Moreover, the




Figure 3. The subpopulation of effector-memory cells in CD8⁺ cells was increased with CpG-ODN. Populations of CD8⁺ cells in harvested cells and CCR7⁺CD45RA⁻ effector-memory T cells among CD8⁺ cells were assessed by flow cytometry.

Ly6K peptide-specific cytotoxicity was induced only with the coexistence of CpG-A, but not with CpG-B and CpG-C. It was suggested that the stimulation of CpG-B or CpG-C was insufficient to elicit Ly6K peptide-specific CTLs because the number of Ly6K peptide-specific precursor CTLs in healthy volunteers is much smaller than that of flu peptide-specific precursor CTLs. These data suggested that CpG-A might be more effective than CpG-B or CpG-C in terms of inducing peptide-specific CTLs *in vitro*.

Our data showed that this CpG-ODN-induced enhancement of cytotoxicity completely disappeared when PDCs were depleted from PBMCs, which means that PDCs were responsible for this enhancement effect. CpG-ODNs mature PDCs by up-regulating the expression of CD80, CD83 and CD86 (21). While most studies have indicated that MoDCs are better antigen-presenters than PDCs (22), many studies have demonstrated the ability of PDCs to function as APCs for both CD4- and CD8-positive cells (22-24). On the other hand, it is well known that CpG-B and CpG-C are more potent to mature PDCs than CpG-A (1,2). Because our data showed that CpG-A was superior to CpG-B and CpG-C in inducing peptide-specific CTLs, the maturation of PDCs by the stimulation of CpG-ODNs

could not affect the results in view of our study design. Therefore, we considered that any cytokines produced from PDCs stimulated by CpG-ODNs must contribute to the enhancement of peptide-specific CTL induction. In addition to IFNs, PDCs also produced the pro-inflammatory cytokines TNF- α and IL-6 (data not shown). Type-1 IFN, TNF- α and IL-6 are known to drive the differentiation of DCs into mature antigen-presentation cells. Our data also showed that the supernatant of PBMCs stimulated by CpG-ODNs up-regulated the expression of CD80, 83 and 86 on monocyte-derived DCs, and the expression level was highest with CpG-A, less with CpG-C, and least with CpG-B (data not shown). However, the production levels of TNF- α and IL-6 from PBMCs stimulated by CpG-A were almost the same as those for CpG-B and CpG-C. Murine PDCs are known to produce IL-12, which induces Th1 differentiation by the stimulation of CpG-ODNs, but human PDCs do not induce IL-12 (25,26). In contrast, CpG-A produced a much higher level of IFN- α than CpG-B or CpG-C, and we considered that the reason why CpG-A has the most potent augmenting effect to induce peptide-specific CTLs is that CpG-A induces the highest level of type-1 IFN from PDCs.




Figure 4. CpG-A augments the Ly6K peptide-specific CTL induction in a PDC-dependent manner. LY6K peptide-specific CTL was generated from 2 different donors in the presence or absence of each class of CpG-ODN (20, 5 and 5 $\mu\text{g}/\text{ml}$ for CpG-A, -B and -C, respectively) as described in Materials and methods. The cytotoxicity of harvested cells against the HLA-A24-positive LCL-A24 cell line pulsed with the LY6K peptide (A and C) or a control HIV peptide (B and D) was assessed by standard ^{51}Cr release assay. PDCs were depleted from PBMCs on day 0. After stimulation with peptide and CpG-A, harvested cells were assessed by standard ^{51}Cr release assay in the same way (E).

Type-1 IFNs are known to activate NK cells (27,28) and induce activation of DCs (29-32). In murine models, it is known that type-1 IFNs promote Th1 cytokine production, effector differentiation, proliferation and contribute to the clonal expansion and formation of memory CD8^+ T cells (33-40).

Our data revealed that the population of CD8^+ cells and that of effector-memory cells in CD8^+ cells after induction of flu peptide-specific CTLs were increased the most with CpG-A, less with CpG-C and least with CpG-B. Memory cells persist for extended periods owing to antigen-independent homeostatic turnover and they respond rapidly upon re-encountering a pathogen (41). Two subsets of memory T cells were described on the basis of their anatomical location, expression of cell surface markers and effector functions (42). Memory T cells that express molecules such as CCR7, which allow efficient homing to lymph nodes (LN), are termed central memory cells (T_{CM}), whereas memory T cells that lack expression of these LN homing receptors and are located in no lymphoid tissues are termed effector memory cells (T_{EM}). Some studies have also shown that T_{EM} acquire effector functions, such as cytokine production and killing, more rapidly than T_{CM} (42-44). The mechanisms that contribute to the generation of memory cells are poorly understood. Previous

studies suggested that infectious antigen-experienced CD8^+ T cells undergo programmed expansion for about 1 week after infection and then undergo programmed cell death (45-47). A majority of the daughter cells derived from antigen-experienced CD8^+ T cells undergo death in parallel with proliferation during the acute phase of viral infection and direct type-I IFN action rescues them from this death, thereby tilting the balance effectively toward clonal expansion (40). Therefore, the type-I IFN-mediated rescue from death during antigen-driven proliferation might be critical for the expansion of memory precursors.

In conclusion, our data showed that the stimulation of PDCs by CpG-ODN augmented the generation of effector-memory peptide-specific CTLs. Furthermore, CpG-A might be superior to CpG-B and CpG-C in augmenting the generation of human peptide-specific CTLs *in vitro*. Therefore, CpG-A could become a superior vaccine adjuvant rather than CpG-B or CpG-C in clinical application.

References

1. Klinman DM: Immunotherapeutic uses of CpG oligodeoxynucleotides. *Nat Rev Immunol* 4: 249-258, 2004.

2. Krieg AM: Therapeutic potential of Toll-like receptor 9 activation. *Nat Rev Drug Discov* 5: 471-484, 2006.
3. Janeway CA Jr: Approaching the asymptote? Evolution and revolution in immunology. *Cold Spring Harb Symp Quant Biol* 54: 1-13, 1989.
4. Marrack P and Kappler J: Subversion of the immune system by pathogens. *Cell* 76: 323-332, 1994.
5. Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC and Romero P: Rapid and strong human CD8⁺ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. *J Clin Invest* 115: 739-746, 2005.
6. Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O'Neill D, Pavlick A, Escalon JB, Cruz CM, Angiulli A, Angiulli F, Mears G, Vogel SM, Pan L, Jungbluth AA, Hoffmann EW, Venhaus R, Ritter G, Old LJ and Ayyoub M: Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. *Proc Natl Acad Sci USA* 104: 8947-8952, 2007.
7. Karbach J, Gnjatich S, Bender A, Neumann A, Weidmann E, Yuan J, Ferrara CA, Hoffmann E, Old LJ, Altorki NK and Jäger E: Tumor-reactive CD8⁺ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. *Int J Cancer* 126: 909-918, 2010.
8. Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR, Sander C, Krieg A, Donnerberg A, Shen H, Kirkwood JM and Zarour HM: Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8⁺ T cells in melanoma patients. *J Immunother* 31: 781-791, 2008.
9. Krieg AM: Antiinfective applications of toll-like receptor 9 agonists. *Proc Am Thorac Soc* 4: 289-294, 2007.
10. Liu YJ: IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. *Annu Rev Immunol* 23: 275-306, 2005.
11. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, Wagner H and Lipford GB: Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. *Proc Natl Acad Sci USA* 98: 9237-9242, 2001.
12. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F and Liu YJ: Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. *J Exp Med* 194: 863-869, 2001.
13. Vollmer J, Jurk M, Samulowitz U, Lipford G, Forsbach A, Willner M, Thuk S, Hartmann H, Kritzler A, Müller C, Schetter C and Krieg AM: CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells. *J Endotoxin Res* 10: 431-438, 2004.
14. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S and Hartmann G: Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. *J Immunol* 168: 4531-4537, 2002.
15. Krieg AM: Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. *Curr Oncol Rep* 6: 88-95, 2004.
16. Martinson JA, Tenorio AR, Montoya CJ, Al-Harthi L, Gichinga CN, Krieg AM, Baum LL and Landay AL: Impact of class A, B and C CpG-oligodeoxynucleotides on *in vitro* activation of innate immune cells in human immunodeficiency virus-1 infected individuals. *Immunology* 120: 526-535, 2007.
17. Marshall JD, Fearon K, Abbate C, Subramanian S, Yee P, Gregorio J, Coffman RL and van Nest G: Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. *J Leukoc Biol* 73: 781-792, 2003.
18. Tanaka H, Tsunoda T, Nukaya I, Sette A, Matsuda K, Umamo Y, Yamaue H, Takesako K and Tanimura H: Mapping the HLA-A24-restricted T-cell epitope peptide from a tumor-associated antigen HER2/neu: possible immunotherapy for colorectal carcinomas. *Br J Cancer* 84: 94-99, 2001.
19. Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Ito H, Miyagi Y, Nakayama H, Fujita M, Hosokawa M, Tsuchiya E, Kohno N, Nakamura Y and Daigo Y: Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. *Cancer Res* 67: 11601-11611, 2007.
20. Rothenfusser S, Hornung V, Ayyoub M, Britsch S, Towarowski A, Krug A, Sarris A, Lubenow N, Speiser D, Endres S and Hartmann G: CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8⁺ T-cell responses *in vitro*. *Blood* 103: 2162-2169, 2004.
21. Fitzgerald-Bocarsly P, Dai J and Singh S: Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. *Cytokine Growth Factor Rev* 19: 3-19, 2008.
22. Grouard G, Risoan MC, Filgueira L, Durand I, Banchereau J and Liu YJ: The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. *J Exp Med* 185: 1101-1111, 1997.
23. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A and Colonna M: Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. *Nat Med* 5: 919-923, 1999.
24. Niessner A, Sato K, Chaikof EL, Colmegna I, Goronzy JJ and Weyand CM: Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha. *Circulation* 114: 2482-2489, 2006.
25. Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, Bals R, Giese T, Engelmann H, Endres S, Krieg AM and Hartmann G: Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. *Eur J Immunol* 31: 3026-3037, 2001.
26. Dzionek A, Inagaki Y, Okawa K, Nagafune J, Röck J, Sohma Y, Winkels G, Zysk M, Yamaguchi Y and Schmitz J: Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. *Hum Immunol* 63: 1133-1148, 2002.
27. Trinchieri G, Santoli D, Dee RR and Knowles BB: Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Identification of the anti-viral activity as interferon and characterization of the human effector lymphocyte subpopulation. *J Exp Med* 147: 1299-1313, 1978.
28. Bandyopadhyay S, Perussia B, Trinchieri G, Miller DS and Starr SE: Requirement for HLA-DR⁺ accessory cells in natural killing of cytomegalovirus-infected fibroblasts. *J Exp Med* 164: 180-195, 1986.
29. Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J and Cebon J: Type I IFNs enhance the terminal differentiation of dendritic cells. *J Immunol* 161: 1947-1953, 1998.
30. Biron CA: Interferons alpha and beta as immune regulators - a new look. *Immunity* 14: 661-664, 2001.
31. Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, Borrow P and Tough DF: Cross-priming of CD8⁺ T cells stimulated by virus-induced type I interferon. *Nat Immunol* 4: 1009-1015, 2003.
32. Krug A, Veeraswamy R, Pekosz A, Kanagawa O, Unanue ER, Colonna M and Cella M: Interferon-producing cells fail to induce proliferation of naive T cells but can promote expansion and T helper 1 differentiation of antigen-experienced unpolarized T cells. *J Exp Med* 197: 899-906, 2003.
33. Cella M, Facchetti F, Lanzavecchia A and Colonna M: Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. *Nat Immunol* 1: 305-310, 2000.
34. Parronchi P, De Carli M, Manetti R, Simonelli C, Sampognaro S, Piccinni MP, Macchia D, Maggi E, Del Prete G and Romagnani S: IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. *J Immunol* 149: 2977-2983, 1992.
35. Wenner CA, Guler ML, Macatonia SE, O'Garra A and Murphy KM: Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development. *J Immunol* 156: 1442-1447, 1996.
36. Marrack P, Kappler J and Mitchell T: Type I interferons keep activated T cells alive. *J Exp Med* 189: 521-530, 1999.
37. Nguyen KB, Watford WT, Salomon R, Hofmann SR, Pien GC, Morinobu A, Gadina M, O'Shea JJ, and Biron CA: Critical role for STAT4 activation by type I interferons in the interferon-gamma response to viral infection. *Science* 297: 2063-2066, 2002.
38. Marrack P and Kappler J: Control of T cell viability. *Annu Rev Immunol* 22: 765-787, 2004.
39. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D and Mescher MF: Cutting edge: type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. *J Immunol* 174: 4465-4469, 2005.

40. Kolumam GA, Thomas S, Thompson LJ, Sprent J and Murali-Krishna K: Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. *J Exp Med* 202: 637-650, 2005.
41. Kaech SM, Wherry EJ and Ahmed R: Effector and memory T-cell differentiation: implications for vaccine development. *Nat Rev Immunol* 2: 251-262, 2002.
42. Sallusto F, Lenig D, Forster R, Lipp M and Lanzavecchia A: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature* 401: 708-712, 1999.
43. Masopust D, Vezys V, Marzo AL and Lefrancois L: Preferential localization of effector memory cells in nonlymphoid tissue. *Science* 291: 2413-2417, 2001.
44. Reinhardt RL, Khoruts A, Merica R, Zell T and Jenkins MK: Visualizing the generation of memory CD4 T cells in the whole body. *Nature* 410: 101-105, 2001.
45. Tanchot C, Lemonnier F, Perarnau B, Freitas A and Rocha B: Differential requirements for survival and proliferation of CD8 naive or memory cells. *Science* 276: 2057-2062, 1997.
46. Ku CC, Murakami M, Sakamoto A, Kappler J and Marrack P: Control of homeostasis of CD8⁺ memory T cells by opposing cytokines. *Science* 288: 675-678, 2000.
47. Schluns KS, Kieper WC, Jameson SC and Lefrancois L: Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells *in vivo*. *Nat Immunol* 1: 426-432, 2000.

Predictive risk factors for clinically relevant pancreatic fistula analyzed in 1,239 patients with pancreaticoduodenectomy: multicenter data collection as a project study of pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery

Manabu Kawai · Satoshi Kondo · Hiroki Yamaue · Keita Wada · Keiji Sano · Fuyuhiko Motoi · Michiaki Unno · Sohei Satoi · A-Hon Kwon · Takashi Hatori · Masakazu Yamamoto · Joe Matsumoto · Yoshiaki Murakami · Ryuichiro Doi · Masahiro Ito · Shuichi Miyakawa · Hiroyuki Shinchi · Shoji Natsugoe · Hisatoshi Nakagawara · Tetsuo Ohta · Tadahiro Takada

Published online: 14 April 2011

© Japanese Society of Hepato-Biliary-Pancreatic Surgery and Springer 2011

Abstract

Background/purpose It is important to predict the development of clinically relevant pancreatic fistula (grade B/C) in the early period after pancreaticoduodenectomy (PD). This study has been carried out as a project study of the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHPBS) to evaluate the predictive factors associated with clinically relevant pancreatic fistula (grade B/C).

Method The data of 1,239 patients from 11 medical institutions who had undergone PD between July 2005 and

June 2009 were retrospectively analyzed to review patient characteristics and perioperative and postoperative parameters.

Results A drain amylase level $>4,000$ IU/L on postoperative day (POD) 1 was proposed as the cut-off level to predict clinical relevant pancreatic fistula by the receiver operating characteristic (ROC) curve. The sensitivity, specificity, and accuracy of this cut-off level were 62.2, 89.0, and 84.8%, respectively. A multivariate logistic regression analysis revealed that male [odds ratio (OR) 1.7,

M. Kawai · H. Yamaue
Second Department of Surgery, School of Medicine,
Wakayama Medical University, Wakayama, Japan

S. Kondo (✉) · J. Matsumoto
Department of Surgical Oncology, Hokkaido University
Graduate School of Medicine, N15 W7, Kita-ku, Sapporo,
Hokkaido 060-8638, Japan
e-mail: info@jshbps.jp

K. Wada · K. Sano
Department of Surgery,
Teikyo University School of Medicine,
Tokyo, Japan

F. Motoi · M. Unno
Division of Hepato-Biliary-Pancreatic Surgery,
Department of Surgery, Tohoku University Graduate
School of Medicine, Sendai, Japan

S. Satoi · A.-H. Kwon
Department of Surgery, Kansai Medical University,
Moriguchi, Osaka, Japan

T. Hatori · M. Yamamoto
Department of Surgery, Institute of Gastroenterology,
Tokyo Women's Medical University,
Tokyo, Japan

Y. Murakami
Division of Clinical Medical Science, Department of Surgery,
Hiroshima University Graduate School of Biomedical Sciences,
Hiroshima, Japan

R. Doi
Department of Hepato-Biliary-Pancreatic Surgery and
Transplantation, Kyoto University, Kyoto, Japan

M. Ito · S. Miyakawa
Department of Biliary Pancreatic Surgery,
Fujita Health University School of Medicine,
Toyoake, Aichi, Japan

H. Shinchi · S. Natsugoe
Department of Surgical Oncology,
Kagoshima University, Kagoshima, Kagoshima, Japan

H. Nakagawara · T. Ohta
Department of Gastroenterological Surgery,
Graduate School of Medical Science,
Kanazawa University, Kanazawa, Ishikawa, Japan

T. Takada
Japanese Society of Hepato-Biliary-Pancreatic Surgery,
Department of Surgery, Teikyo University School
of Medicine, Tokyo, Japan

$P = 0.039$], intraoperative bleeding $>1,000$ ml (OR 2.5, $P = 0.001$), soft pancreas (OR 2.7, $P = 0.001$), and drain amylase level on POD 1 $>4,000$ IU/L (OR 8.6, $P < 0.001$) were the significant predictive factors for clinical pancreatic fistula.

Conclusion The four predictive risk factors identified here can provide useful information useful for tailoring postoperative management of clinically relevant pancreatic fistula (grade B/C).

Keywords Pancreatic fistula · Pancreaticoduodenectomy · Predictive risk factors · Drain amylase level

Introduction

In most patient series, the incidence of pancreatic fistula has been reported to vary between 5 and 20% after pancreaticoduodenectomy (PD) and to be associated with a high mortality rate [1–7]. In 2005, the International Study Group of Pancreatic Fistula (ISGPF) proposed a consensus definition and clinical grading of postoperative pancreatic fistula [8]. The most important issue currently being debated regarding pancreatic fistulas is whether it is possible to predict the development of clinically relevant pancreatic fistula (grade B/C) according to the ISGPF proposal in the early period after PD. The risk factors for developing a pancreatic fistula in previously reported studies may have been able to predict all grades of pancreatic fistulas but, unfortunately, could not predict the extent of severe clinically relevant pancreatic fistula (grade B/C) [9–13].

Molinari et al. [14] proposed that a drain amylase value on postoperative day (POD) 1 of $>5,000$ U/L was a significant predictive factor for the incidence of all grades of pancreatic fistula after PD. However, this amylase value could not distinguish clinically relevant pancreatic fistulas (grade B/C) from insignificant disease during the early postoperative period. Kawai et al. proposed that a combination of two predictive postoperative factors on POD 4, namely, serum albumin level ≤ 3.0 g/dL and leukocyte counts $>9,800/\text{mm}^3$, can predict the development of clinically relevant pancreatic fistula [15]. However, these two factors may also reflect serious systemic inflammation, such as that due to other intra-abdominal or respiratory complications. It therefore remains unclear which predictive risk factor(s) can be used to precisely distinguish the risk of clinically relevant pancreatic fistula (grade B/C) in the early postoperative period. In an attempt to clarify this situation, the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHPBS) decided to perform a survey of high-volume PD centers in Japan to evaluate the predictive factors for the development of clinically relevant pancreatic fistula (grade B/C) in the early period after PD.

Methods

Patients

Data were collected by a questionnaire survey on all patients who underwent PD between July 2005 and June 2009 at one of 11 high-volume centers participating in the project study of the JSHPBS. The following patient characteristics and perioperative and postoperative parameters were reviewed: age, gender, body mass index (BMI), American Society of Anesthesiologists (ASA) class, preoperative laboratory data, such as hemoglobin, creatinine, HbA1c (glycated hemoglobin), albumin, total bilirubin, and amylase, preoperative biliary drainage, length of the surgery, intraoperative bleeding, blood transfusion, pancreatic texture (soft or hard), presence or absence of dilatation of the main pancreatic duct, histologic diagnosis (malignant or benign), and the serum C-reactive protein (CPR) and drain amylase levels on POD 1, 3, and 4. In total, data on 1,331 patients were collected from the 11 institutions. Of these 1,331 patients, 1,239 (749 men, 490 women; median age 67 years, age range 35–91 years) were enrolled in the study, and their data used for the analysis of the occurrence of pancreatic fistula using the ISGPF criteria.

Postoperative complications

The diagnosis of pancreatic fistula was made based on the ISGPF guidelines [8], namely, an amylase level in the drainage fluid on POD 3 of more than threefold the serum amylase level. Pancreatic fistulas were classified into three categories according to the ISGPF guidelines:

Grade A: Transient fistula. There is no clinical impact. The patient is fed orally and remains clinically well.

Grade B: Patients are usually supported with partial, total parenteral, or enteral nutrition. Antibiotics are usually used for signs of infections and a somatostatin analogue may also be required. Percutaneous drainage or persistent drainage for more than 3 weeks is usually required.

Grade C: A major change in clinical management or deviation from the normal clinical pathway. Total parenteral, enteral nutrition, antibiotics, or somatostatin analogue is often instituted in an intensive care unit (ICU) setting. Radiologic intervention or reoperation is required. The patients typically require an extended hospital stay with a major delay in hospital discharge and have life-threatening complications, such as intra-abdominal bleeding or sepsis. There is a real possibility of postoperative mortality [8].

Grades B + C were defined as “clinically relevant pancreatic fistula”. Delayed gastric emptying (DGE) was

defined according to a consensus definition and the clinical grading of postoperative DGE according to the proposals of the International Study Group of Pancreatic Surgery (ISGPS) [16], using the web-based calculator (<http://pancreasclub.com/calculator/>) to improve the homogeneity of the definition [17]. DGE was then classified into three categories (grade A, B, or C) by the ISGPS clinical criteria based on the clinical course and postoperative management, such as reinsertion of a nasogastric tube, the period of inability to tolerate a solid diet, presence or absence of vomiting, and the use of prokinetics. Other postoperative complications were graded according to the Clavien classification [18], where grade I is any deviation from the normal postoperative course but without any need for pharmacologic treatment or surgical, endoscopic, or radiologic intervention; grade II is indicated by complications requiring pharmacologic treatment; grade III, by complications requiring surgical, endoscopic, or radiologic intervention; grade IV, life-threatening complications requiring intermediate or ICU management; grade V, death. Complications in this study were defined as a condition that was more than grade II according to the Clavien classification.

Statistical analysis

Continuous variables were expressed as the mean \pm standard deviation (SD). Patient characteristics and perioperative and postoperative factors between the groups were compared using chi-square statistics, the Fisher exact test, and the Mann–Whitney *U* test. Variables with $P < 0.05$ were entered into a logistic regression model to determine independent risk factors of postoperative complications. The independent risk factors of the variables were expressed as odds ratios (OR) with their 95% confidence intervals (CI). The measurement of drain amylase levels on POD 1 has a major benefit by enabling the development of clinically relevant pancreatic fistula (grade B/C) to be predicted in the early period after PD. In fact, amylase values in drains on POD 1 of $>5,000$ U/L have been reported to be a significant predictive factor for the incidence of all grades of pancreatic fistula after PD [14]. Therefore, the optimal cut-off levels of the drain amylase level on POD 1 for differentiation between the no pancreatic fistula/grade A group and the grade B/C group were sought by constructing receiver operating characteristic (ROC) curves, which were generated by calculating the sensitivities and specificities of the drain amylase level on POD 1 at several predetermined cut-off points. Line graphs were used for graphical visualization (SPSS, Chicago, IL). Statistical significance was defined as $P < 0.05$.

Results

The indications for PD in the 1,239 patients were 573 pancreatic adenocarcinoma, 237 bile duct carcinoma, 124 ampullary adenocarcinoma, 127 intraductal papillary neoplasms, 38 duodenal adenocarcinoma, 37 pancreatic endocrine neoplasms, 46 tumor-forming pancreatitis, and 57 “other” diseases.

Postoperative complications

Table 1 shows the postoperative complications among the patient cohort after PD. The overall morbidity was 44.2% (548/1,239 patients). The overall rate of pancreatic fistula was 30.2% (374 patients). When the pancreatic fistula was classified into the three categories according to the ISGPF criteria, 15.8% (196/1,239) of the patients had grade A fistula; 11.8% (146 patients) had grade B; 2.6% (32 patients) had grade C. In total 139 (11.2%) patients had intra-abdominal abscess, and 58 patients (4.7%) required percutaneous drainage for the development of intra-abdominal abscess related to pancreatic fistula after PD. The reoperation rate due to pancreatic fistula was 0.72% (9/1,239 patients), and the overall incidence of DGE was 16.9% (211/1,239 patients). The DGE was categorized according to the ISGPS guidelines into grade A (107 patients, 9.6%), grade B (51 patients, 4.1%), and grade C (53 patients, 4.3%). The overall mortality rate was 0.97% (12/1,239 patients).

Comparison of patient characteristics, intraoperative status, and postoperative outcome among types of pancreatic fistula

Table 2 shows the general characteristics, intraoperative status, and postoperative outcome of the 1,239 patients classified by ISGPF. Based on the ISGPF criteria, 865 of the 1,239 patients (69.8%) did not develop a pancreatic fistula, and 196 patients (15.8%) developed only transient pancreatic fistula (grade A), while a clinically relevant pancreatic fistula (grade B/C) developed in 178 patients (14.4%). The ratio of male to female patients was significantly higher in those patients with a grade B/C fistula than in those with no pancreatic fistula or a grade A fistula. In those patients with a grade B/C fistula, the length of the surgery was significantly longer, and the intraoperative bleeding or the need for blood transfusion was significantly higher, compared to subjects with no pancreatic fistula or a grade A fistula. Patients with soft pancreatic parenchyma or a pancreatic duct <3 mm had a significantly higher incidence of pancreatic fistula (grade A and grade B/C) than those with no pancreatic fistula ($P < 0.01$). There were no

Table 1 Postoperative complications and the outcome after 1,239 pancreaticoduodenectomies

Postoperative complications/outcome	No. of patients (%)
Overall morbidity	548 (44.2)
Local complication	
Pancreatic fistula ^a	374 (30.2)
Grade A	196 (15.8)
Grade B	146 (11.8)
Grade C	32 (2.6)
Intra-abdominal abscess	139 (11.2)
Intra-abdominal bleeding	34 (2.7)
Biliary leakage	29 (2.3)
Gastrointestinal leakage	72 (5.8)
Delayed gastric emptying ^b	211 (16.9)
Grade A	107 (9.6)
Grade B	51 (4.1)
Grade C	53 (4.3)
Wound infection	130 (10.5)
Systemic complications	
Cardiac complication	35 (2.8)
Pulmonary complications	23 (1.9)
Sepsis	35 (2.8)
Percutaneous drainage	58 (4.7)
Persisting drain (more than 3 weeks) ^c	104 (8.4)
Reoperation	9 (0.7)
Mortality	12 (1.0)

^a Pancreatic fistula as defined by the International Study Group of Pancreatic Fistula (ISGPF)

^b Delayed gastric emptying as defined by the International Study Group of Pancreatic Surgery (ISGPS)

^c Used in postoperative management of intra-abdominal abscess related to pancreatic fistula

significant differences between patients with grade A and grade B/C pancreatic fistula in term of the presence of soft pancreatic parenchyma or pancreatic duct <3 mm.

With regard to the postoperative outcome, the drain amylase level on POD 1 in the grade B/C group ($18,846 \pm 37,287$ IU/L) was significantly higher than that in the grade A group ($7,951 \pm 15,322$ IU/L) ($P = 0.002$), whereas there was no significant difference between the grade A group and grade B/C group in terms of drain amylase level on POD 3 and 4.

Predictive factors for the development of a clinically relevant pancreatic fistula (grade B/C)

With regard to the sensitivity and specificity of the drain amylase level on POD 1, an area under the ROC curve of 0.840 was obtained ($P < 0.001$; 95% confidence interval:

0.807–0.874) (Fig. 1). Drain amylase level >4,000 IU/l on POD 1 was suggested to be the best cut-off for prediction of the clinically relevant pancreatic fistula. The sensitivity, specificity, accuracy, positive predictive value and negative predictive value of drain amylase level on POD1 >4,000 IU/l were 62.2, 89.0, 84.8, 51.1 and 92.7%, respectively.

Univariate and multivariate analysis were used to reveal those factors predicting grade B/C pancreatic fistula. Table 3 presents the results of the univariate analysis of 18 parameters as potential risk factors in the 178 patients with clinically relevant pancreatic fistula (grade B/C) versus 1,061 patients with no pancreatic fistula or with transient pancreatic fistula (grade A). Nine factors were extracted and identified as being useful for discriminating between those who would develop grade B/C fistula and those who would not develop a fistula or would develop only grade A fistula: (1) preoperative factors, namely, male gender ($P < 0.001$), BMI >25 kg/m² ($P = 0.005$), HbA1c >7.0% ($P = 0.001$), and creatinine >1.5 mg/dL ($P = 0.039$); (2) intraoperative factors, namely, operative time >480 min ($P = 0.012$), intraoperative bleeding >1,000 mL ($P = 0.001$), soft pancreatic parenchyma ($P < 0.001$), and main pancreatic duct <3 mm ($P < 0.001$); (3) one postoperative factor, namely, drain amylase level on POD 1 >4,000 IU/L ($P < 0.001$). A multivariate logistic regression analysis revealed that male gender (OR 1.7, 95% CI 1.0–3.0, $P = 0.039$), intraoperative bleeding >1,000 mL (OR 2.5, 95% CI 1.4–4.6, $P = 0.001$), soft pancreatic parenchyma (OR 2.7, 95% CI 1.5–4.8, $P = 0.001$), and drain amylase level on POD 1 >4,000 IU/L (OR 8.6, 95% CI 5.2–14.2, $P < 0.001$) were the significant predictive factors for developing clinically relevant pancreatic fistula of grade B/C (Table 4).

Discussion

The development of pancreatic fistula has been reported to be a potentially life-threatening complication after PD [19–21]. Although lower grade fistula can still complicate patient recovery, it is very important to be able to predict whether a patient will develop clinically relevant pancreatic fistula (grade B/C) in the early period after PD, since these fistulas require changes in patient management and are associated with a higher mortality rate. This study was conducted as a project study of the JSHPBS and was designed to evaluate the predictive factors associated with the development of a clinically relevant pancreatic fistula (grade B/C) after PD. We found that male gender, intraoperative bleeding >1,000 mL, soft pancreatic parenchyma, and drain amylase level on POD 1 of >4,000 IU/L were the most significant predictive factors of the development of clinically relevant pancreatic fistula (grade B/C).

Table 2 Comparison of patient characteristics, intraoperative status, and postoperative outcome among types of pancreatic fistula

Patient characteristics, intraoperative status, and postoperative outcome	Pancreatic fistula		
	(-) (<i>n</i> = 865)	Grade A (<i>n</i> = 196)	Grade B/C (<i>n</i> = 178)
Patient characteristics			
Age (years)	66 ± 11	67 ± 10	67 ± 9
Gender (male/female)	507/358	110/86	132/46 ^c
Body mass index (kg/m ²)	21.5 ± 3.4	21.7 ± 3.0	22.6 ± 3.3
ASA (I–II/III–IV)	740/122	172/24	144/33
Preoperative serum bilirubin level (mg/dl)	3.1 ± 4.6	2.9 ± 4.5	3.4 ± 5.9
Preoperative biliary drainage (%)	46.2	41.8	49.4
Preoperative hemoglobin (g/dL)	12.4 ± 1.6	12.3 ± 1.8	12.7 ± 1.7
Preoperative creatinine (mg/dL)	0.8 ± 10.6	0.8 ± 0.5	1.0 ± 1.0
HbA1c (%)	6.3 ± 4.5	5.8 ± 1.3	5.5 ± 0.9
Preoperative serum albumin (g/dL)	3.9 ± 0.5	3.9 ± 0.5	3.8 ± 0.5
Preoperative serum amylase (IU/L)	139 ± 244	137 ± 162	125 ± 113
Histology (benign/malignant)	132/696	43/144	35/132
Intraoperative status			
Operative time (min)	480 ± 144	456 ± 133	542 ± 403 ^c
Intraoperative bleeding (mL)	1,215 ± 1,168	1,170 ± 1,056	1,596 ± 1,849 ^c
Red blood cell transfusion (unit)	1.8 ± 3.9	1.7 ± 2.8	2.9 ± 6.2 ^c
Pancreatic duct (>3 mm/<3 mm)	573/170	99/77 ^a	76/90 ^b
Soft pancreatic texture (soft/hard)	355/510	151/45 ^a	142/36 ^b
Postoperative outcome			
CRP on POD 1 (mg/dL)	9.1 ± 22.0	8.6 ± 3.3	9.3 ± 3.8
CRP on POD 3 (mg/dL)	12.0 ± 5.95	15.8 ± 7.4 ^a	20.0 ± 7.2 ^c
CRP on POD 4 (mg/dL)	8.35 ± 5.95	12.2 ± 6.1 ^a	15.7 ± 6.7 ^c
WBC on POD 1 (/mm ³)	10,167 ± 3,367	10,636 ± 3,757	10,380 ± 4,163
WBC on POD 3 (/mm ³)	9,127 ± 5,024	10,489 ± 3,562 ^a	10,674 ± 3,840 ^b
WBC on POD 4 (/mm ³)	7,677 ± 6,169	8,799 ± 3,168 ^a	9,735 ± 3,529 ^b
Albumin on POD 1 (g/dL)	2.8 ± 1.0	2.9 ± 0.5	2.9 ± 0.5
Albumin on POD 3 (g/dL)	2.8 ± 0.5	2.8 ± 0.5	2.7 ± 0.5
Albumin on POD 4 (g/dL)	2.9 ± 0.6	3.0 ± 0.6	2.7 ± 0.4 ^b
Amylase level of drainage fluid			
POD 1 (IU/L)	1,058 ± 2,186	7,951 ± 15,322 ^a	18,846 ± 37,278 ^c
POD 3 (IU/L)	134 ± 181	3,638 ± 10,711 ^a	6,284 ± 15,183 ^c
POD 4 (IU/L)	79 ± 136	2,375 ± 9,565 ^a	5,325 ± 18,452 ^c
Postoperative hospital stay (days)	28 ± 18	29 ± 20	56 ± 40 ^c

Data are given as the mean ± standard deviation (SD) unless otherwise indicated

ASA American Society of Anesthesiologists, HbA1c hemoglobin A1C (glycated hemoglobin), CRP C-reactive protein, WBC white blood cells, POD postoperative day

^a No pancreatic fistula vs. grade A, *P* < 0.01

^b No pancreatic fistula vs. grade B + C, *P* < 0.01

^c No pancreatic fistula vs. grade B + C, *P* < 0.01 and grade A vs. grade B + C, *P* < 0.01

In particular, a drain amylase value >4,000 U/L on POD 1 correlated with 8.6-fold increased risk of developing clinically relevant pancreatic fistula.

Some authors have proposed that drain-related data, including the drain amylase level, are useful for defining the

risk of developing a pancreatic fistula after PD [14, 22, 23], including Molinari et al. [14], who suggested that a drain amylase value on POD 1 >5,000 U/L was a significant predictive factor for the incidence of pancreatic fistula. However, the latter study was limited due to the small sample




Fig. 1 Receiver operating characteristic (ROC) curves fore drain amylase level on postoperative day (POD 1) to predict clinically relevant pancreatic fistula (grade B/C). An area under the ROC curve of 0.841 was obtained taking the sensitivity and specificity of the drain amylase level on POD 1 into consideration [$P < 0.001$, 95% confidence interval (CI) 0.806–0.876]. A drain amylase level $>4,000$ IU/l on POD 1 was therefore suggested to be the best cut-off for predicting the clinical occurrence pancreatic fistula

size ($n = 137$). Moreover, of the 137 patients enrolled in the study, 36 patients underwent distal pancreatectomy, and 12 (44%) of the 27 patients with pancreatic fistula reported in their results underwent distal pancreatectomy, not PD [14]. In these three studies [14, 22, 23], clinically relevant pancreatic fistula (grade B/C) could not be distinguished from transient (grade A) fistula in the early postoperative period solely based on the drain amylase value. In three other studies [15, 24, 25], the authors were unable to determine whether the drain amylase value was reflective of clinically relevant pancreatic fistula, although they did propose the evaluation of predictive risk factors, such as the presence of soft pancreas, intra-abdominal bleeding, and the postoperative albumin level, as indicators for the development of clinically relevant pancreatic fistula. To the best of our knowledge, our study is the first published report demonstrating that the drain amylase value on POD 1 can predict the development of clinically relevant pancreatic fistula (grade B/C). Therefore, based on the results of this study, early removal of drains can be done when the drain amylase value is $<4,000$ U/L on POD 1 because these patients are unlikely to develop clinically relevant fistula. Moreover, early drain removal has previously been demonstrated to play a critical role in reducing the incidence of pancreatic fistula or intra-abdominal abscess [26, 27].

Table 3 A univariate analysis of the predictive factors for clinical relevant pancreatic fistula (ISGPF grade B/C)

Predictive factors	Pancreatic fistula grade B/C		P value
	(-) ($n = 1,061$)	(+) ($n = 178$)	
Age ($>75/\leq 75$ years)	202/859	31/147	0.608
Gender (male/female)	617/444	132/46	<0.001
BMI ($>25/\leq 25$ kg/m ²)	142/919	38/140	0.005
ASA (I–II/III–IV)	146/912	33/144	0.090
COPD (yes/no)	59/1,001	11/167	0.871
HbA1c ($>7.0/\leq 7.0\%$)	181/743	15/129	0.008
Hemoglobin ($>12/\leq 12$ g/dL)	647/410	120/58	0.114
Creatinine ($>1.2/\leq 1.25$ mg/dL)	32/975	11/162	0.039
Albumin ($>3.5/\leq 3.5$ g/dL)	857/198	139/37	0.539
Total bilirubin ($>5/\leq 5$ mg/dL)	212/846	36/142	0.776
Amylase ($>180/\leq 180$ IU/L)	186/865	26/152	0.257
Preoperative biliary drainage (yes/no)	482/579	88/90	0.321
Operation time ($>480/\leq 480$ min)	470/591	97/81	0.012
Intraoperative bleeding ($>1,000/\leq 1,000$ mL)	478/583	105/73	0.001
Blood transfusion (yes/no)	344/717	69/109	0.097
Pancreatic texture (soft/hard)	506/555	142/36	<0.001
Main pancreatic duct ($<3/\geq 3$ mm)	247/672	90/76	<0.001
Amylase level of drainage fluid on POD 1 (IU/L) ($\leq 4,000/>4,000$)	712/88	56/92	<0.001

BMI body mass index, COPD chronic obstructive pulmonary disease

Table 4 Multivariate analysis of the predictive factors for clinical relevant pancreatic fistula (ISGPF grade B/C) and predictive score

Risk factor	P value	Odds ratio	95% Confidence interval
Male	0.039	1.7	1.0–3.0
Intraoperative bleeding >1,000 ml	0.001	2.5	1.5–4.2
Soft pancreas	0.001	2.7	1.5–4.8
Amylase level of drainage fluid on POD 1 (IU/L) >4,000 IU/L	<0.0001	8.6	5.2–14.2

In contrast, the authors of a number of other studies have found that the amylase level in drainage fluid after PD has no clinical significance [28, 29]. The ISGPF has proposed that the ability to detect pancreatic fistula is imperfect when only drain data are used [28]. Two factors may underlie this low predictive ability: first, there have been patients who ultimately demonstrated no clinically relevant symptoms of pancreatic fistula despite having amylase-rich fluid on POD 1; second, there was the pattern of pancreatic fistula defined by Pratt et al. [30] as latent pancreatic fistula. Latent fistulas have been defined as initially lacking amylase-rich fluid but ultimately becoming clinically relevant pancreatic fistula (grade B/C). Pratt et al. [30] proposed that advanced age and small pancreatic duct size were significantly associated with latent fistulas.

There are several limitations to our study because of the multicenter and retrospective nature of the data collection. First, the surgical procedures, such as pancreaticoenterostomy (pancreaticogastrostomy or pancreaticojejunostomy) or use of pancreatic duct stent (internal, external, or no stent), were not standardized across institutions. Second, drain management, such as the number of drains, location of placed drains, or drain type, varied widely according to institutional experience. There were cases which ultimately demonstrated no clinically relevant symptoms of pancreatic fistula despite having amylase-rich fluid on POD 1. In fact, 48.9% of patients with a drain amylase value >4,000 U/L on POD 1 did not develop a clinically relevant pancreatic fistula. Therefore, further studies are necessary to prospectively validate these predictive risk factors to confirm the possible relationship between these factors and the development of clinically relevant pancreatic fistula (grade B/C).

In conclusion, the results of this study, which was an initiative of the JSHPBS, indicated that male gender, soft pancreas, intraoperative bleeding >1,000 ml, and amylase value >4,000 U/L in drains on POD 1 were significant predictive risk factors for developing clinically relevant pancreatic fistula (grade B/C). Management of pancreatic fistula in the early period after PD is not sufficiently

standardized. Therefore, the identification of these predictive risk factors can provide useful information to tailor the postoperative management for patients who are at an increased risk of developing pancreatic fistula, including drain management, and the administration of antibiotics, a protease inhibitor, octreotide, or enteral nutrition.

References

1. McPhee JT, Hill JS, Whalen GF, Zayaruzny M, Litwin DE, Sullivan ME, et al. Perioperative mortality for pancreatotomy. A national perspective. *Ann Surg.* 2007;246:246–53.
2. Büchler MW, Wagner M, Schmied BM, Uhl W, Friess H, Z'graggen K. Changes in morbidity after pancreatic resection. Toward the end of completion pancreatotomy. *Arch Surg.* 2003;138:1310–4.
3. Tani M, Terasawa H, Kawai M, Ina S, Hirono S, Uchiyama K, et al. Improvement of delayed gastric emptying in pylorus-preserving pancreaticoduodenectomy: results of a prospective, randomized, controlled trial. *Ann Surg.* 2006;243:316–20.
4. Balcom JH, Rattner DW, Warshaw AL, Chang Y, Castillo CF. Ten-year experience with 733 pancreatic resections. Changing indications, older patients, and decreasing length of hospitalization. *Arch Surg.* 2001;136:391–8.
5. Kazanjian KK, Hines OJ, Eibl G, Reber HA. Management of pancreatic fistulas after pancreaticoduodenectomy: results in 437 consecutive patients. *Arch Surg.* 2005;140:849–54.
6. DeOliveira ML, Winter JM, Schafer M, Cunningham SC, Cameron JL, Yeo CJ, et al. Assessment of complications after pancreatic surgery: a novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. *Ann Surg.* 2006;244:931–7.
7. Tani M, Kawai M, Hirono S, Ina S, Miyazawa M, Shimizu A, et al. A prospective randomized controlled trial of internal versus external drainage with pancreaticojejunostomy for pancreaticoduodenectomy. *Am J Surg.* 2010;199:759–64.
8. Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al. International Study Group on Pancreatic Fistula Definition. Postoperative pancreatic fistula: an international study group (ISGPF) definition. *Surgery.* 2005;138:8–13.
9. Wada K, Traverso LW. Pancreatic anastomotic leak after the Whipple procedure is reduced using the surgical microscope. *Surgery.* 2006;139:735–42.
10. Poon RT, Fan ST, Lo CM, Ng KK, Yuen WK, Yeung C, Wong J. External drainage of pancreatic duct with a stent to reduce leakage rate of pancreaticojejunostomy after pancreaticoduodenectomy: a prospective randomized trial. *Ann Surg.* 2007;246:425–33.
11. Adam U, Makowiec F, Riediger H, Schareck WD, Benz S, Hopt UT. Risk factors for complications after pancreatic head resection. *Am J Surg.* 2004;187:201–8.
12. Sato N, Yamaguchi K, Chijiwa K, Tanaka M. Risk analysis of pancreatic fistula after pancreatic head resection. *Arch Surg.* 1998;133:1094–8.
13. Bottger TC, Junginger T. Factors influencing morbidity and mortality after pancreaticoduodenectomy: critical analysis of 221 resections. *World J Surg.* 1999;23:164–71. discussion 171–2.
14. Molinari E, Bassi C, Salvia R, Butturini G, Crippa S, Talamini G, et al. Amylase value in drains after pancreatic resection as predictive factor of postoperative pancreatic fistula: results of a prospective study in 137 patients. *Ann Surg.* 2007;246:281–7.

15. Kawai M, Tani M, Hirono S, Ina S, Miyazawa M, Yamaue H. How do we predict the clinically relevant pancreatic fistula after pancreaticoduodenectomy? An analysis in 244 consecutive patients. *World J Surg.* 2009;33:2670–8.
16. Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). *Surgery.* 2007;142:761–8.
17. Hashimoto Y, Traverso LW. Incidence of pancreatic anastomotic failure and delayed gastric emptying after pancreatoduodenectomy in 507 consecutive patients: use of a web-based calculator to improve homogeneity of definition. *Surgery.* 2010;147:503–15.
18. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg.* 2004;240:205–13.
19. Akamatsu N, Sugawara Y, Komagome M, Shin N, Cho N, Ishida T, et al. Risk factors for postoperative pancreatic fistula after pancreaticoduodenectomy: the significance of the ratio of the main pancreatic duct to the pancreas body as a predictor of leakage. *J Hepatobiliary Pancreat Sci.* 2010;17:322–8.
20. Parr ZE, Sutherland FR, Bathe OF, Dixon E. Pancreatic fistulae: are we making progress? *J Hepatobiliary Pancreat Surg.* 2008;15:563–9.
21. Okabayashi T, Kobayashi M, Nishimori I, Sugimoto T, Onishi S, Hanazaki K. Risk factors, predictors and prevention of pancreatic fistula formation after pancreatoduodenectomy. *J Hepatobiliary Pancreat Surg.* 2007;14:557–63.
22. Shinchi H, Wada K, Traverso LW. The usefulness of drain data to identify a clinically relevant pancreatic anastomotic leak after pancreaticoduodenectomy? *J Gastrointest Surg.* 2006;10:490–8.
23. Yamaguchi M, Nakano H, Midorikawa T, Yoshizawa Y, Sanada Y, Kumada K. Prediction of pancreatic fistula by amylase levels of drainage fluid on the first day after pancreatectomy. *Hepato-gastroenterology.* 2003;50:1155–8.
24. Pratt WB, Callery MP, Vollmer CM Jr. Risk prediction for development of pancreatic fistula using the ISGPF classification scheme. *World J Surg.* 2008;32:419–28.
25. Fuks D, Piessen G, Huet E, Tavernier M, Zerbib P, Michot F, et al. Life-threatening postoperative pancreatic fistula (grade C) after pancreaticoduodenectomy: incidence, prognosis, and risk factors. *Am J Surg.* 2009;197:702–9.
26. Kawai M, Tani M, Terasawa H, Ina S, Hirono S, Nishioka R. Early removal of prophylactic drains reduces the risk of intra-abdominal infections in patients with pancreatic head resection: prospective study for consecutive 104 patients. *Ann Surg.* 2006;244:1–7.
27. Bassi C, Molinari E, Malleo G, Crippa S, Butturini G, Salvia R. Early versus late drain removal after standard pancreatic resections: results of a prospective randomized trial. *Ann Surg.* 2010;252:207–14.
28. Reid-Lombardo KM, Farnell MB, Crippa S, Barnett M, Maupin G, Bassi C, et al. Pancreatic anastomotic leakage after pancreaticoduodenectomy in 1,507 patients: a report from the Pancreatic Anastomotic Leak Study Group. *J Gastrointest Surg.* 2007;11:1451–8. discussion 1459.
29. Shyr YM, Su CH, Wu CW, Lui WY. Does drainage fluid amylase reflect pancreatic leakage after pancreaticoduodenectomy? *World J Surg.* 2003;27:606–10.
30. Pratt WB, Callery MP, Vollmer CM Jr. The latent presentation of pancreatic fistulas. *Br J Surg.* 2009;96:641–9.

Pancreaticoduodenectomy versus pylorus-preserving pancreaticoduodenectomy: the clinical impact of a new surgical procedure; pylorus-resecting pancreaticoduodenectomy

Manabu Kawai · Hiroki Yamaue

Published online: 23 August 2011

© Japanese Society of Hepato-Biliary-Pancreatic Surgery and Springer 2011

Abstract Pylorus-preserving pancreaticoduodenectomy (PpPD) has been performed increasingly for periampullary tumors as a modification of conventional pancreaticoduodenectomy (PD) with antrectomy. Five randomized controlled trials (RCTs) and two meta-analyses have been performed to compare PD with PpPD. The results of these trials have shown that the two procedures were equally effective concerning morbidity, mortality, quality of life (QOL), and survival, although the length of surgery and blood loss were significantly lower for PpPD than for PD in one RCT and in the two meta-analyses. Delayed gastric emptying (DGE) is the major postoperative complication after PpPD. One of the pathogeneses of DGE after PpPD is thought to be denervation or devascularization around the pyloric ring. Therefore, one RCT was performed to compare PpPD with pylorus-resecting pancreaticoduodenectomy (PrPD; a new PD surgical procedure that resects only the pyloric ring and preserves nearly all of the stomach), concerning the incidence of DGE. The results clarified that the incidence of DGE was 4.5% after PrPD and 17.2% after PpPD, which was a significant difference. Several RCTs of surgical or postoperative management techniques have been performed to reduce the incidence of DGE. One RCT for surgical techniques clarified that the antecolic route for duodenojejunostomy significantly reduced the incidence of DGE compared with the retrocolic route. Two RCTs examining postoperative management showed that the administration of erythromycin after PpPD reduced the incidence of DGE.

Keywords Pancreaticoduodenectomy · Pylorus-preserving pancreaticoduodenectomy · Pylorus-resecting pancreaticoduodenectomy · Delayed gastric emptying

Introduction

Pancreaticoduodenectomy (PD) was first performed by Kausch [1] and was later developed by Whipple and colleagues for the treatment of carcinoma of the ampulla of Vater [2]. Conversely, pylorus-preserving pancreaticoduodenectomy (PpPD) with preservation of the entire stomach was described by Watson [3], and was popularized for the treatment of chronic pancreatitis as a modification of conventional PD with antrectomy reported by Traverso and Longmire in the late 1970s [4]. PpPD has been thought to reduce dumping syndrome, diarrhea, and bile reflux gastritis after gastrectomy and to afford patients an improved nutritional status compared to PD with antrectomy. Several reports have discussed whether preservation of the pylorus can provide a better nutritional status and more favorable quality of life (QOL) compared with PD [5–12]. However, the difference between PD and PpPD concerning long-term nutrition and QOL remains controversial.

The incidence of morbidities after PpPD remains high, in the range of 30–65%, although the mortality rate has dropped to below 5% as a result of advances in surgical techniques and perioperative management [13–17]. Delayed gastric emptying (DGE) after PpPD may occur with an incidence varying from 12 to 42%, as reported in previous series [12, 18–22]. One retrospective study reported that PpPD led to an increased incidence of DGE compared with PD [21]. At the same time, other studies have observed no difference in the incidence of DGE between PD and PpPD [6, 7, 22]. The impact of pylorus

M. Kawai · H. Yamaue (✉)
Second Department of Surgery, Wakayama Medical University,
School of Medicine, 811-1 Kimiidera, Wakayama 641-8510,
Japan
e-mail: yamaue-h@wakayama-med.ac.jp

preservation in patients undergoing PD for periampullary tumors has remained controversial concerning morbidity, mortality, QOL, and long-term survival.

Several randomized controlled trials (RCTs) or meta-analyses comparing PpPD and PD have been performed [23–29]. This review summarizes the findings of the RCTs comparing PD with PpPD and describes a new PD surgical procedure with resection of only the pyloric ring with preservation of nearly all of the stomach–pylorus–resecting pancreaticoduodenectomy (PrPD) [30].

Pylorus-preserving pancreaticoduodenectomy versus pancreaticoduodenectomy

Morbidity and mortality

Five RCTs comparing PD with PpPD have been performed at three institutions (Table 1) [23–27]. Concerning intra-operative factors, Seiler et al. [26] reported that the length of surgery, blood loss, and the volume of blood transfusions were all significantly lower for PpPD ($n = 64$) than PD ($n = 66$).

Concerning the incidence of postoperative complications, the five RCTs revealed no significant differences in the incidence of postoperative complications such as pancreatic fistula, intra-abdominal abscess, or intra-abdominal bleeding between patients who underwent PD and those who underwent PpPD. However, the development of DGE after PpPD is a persistent and frustrating complication. Lin et al. [27] reported that DGE occurred more frequently with PpPD (6 of 14 patients; 42.8%) than with PD (0 of 19 patients; 0%) ($P < 0.05$). However, the sample size of this RCT was small ($n = 33$) and the RCT was limited to patients with pancreatic head cancer. On the other hand, Tran et al. reported in their RCT that there was no significant difference between PpPD (19 of 85 patients; 22%)

and PD (18 of 80 patients; 23%) concerning the incidence of DGE [25]. Seiler et al. [26] also reported that there was no significant difference between PpPD (30 of 66 patients; 45%) and PD (20 of 64 patients; 31%) with regard to the incidence of DGE. Two meta-analyses suggested that there were no significant differences in postoperative complications, including DGE, between PD and PpPD [28, 29]. PD had a mortality range of 0–7%, while the mortality due to PpPD ranged from 3 to 11% in the five RCTs. There were no significant differences between the two procedures with regard to mortality. Therefore, the two procedures were equally effective for periampullary tumors in terms of morbidity and mortality.

Quality of life and survival

Table 2 shows the comparison in long-term outcome between patients treated by PD and those treated by PpPD concerning to changes in body weight and QOL [6–10, 20–22, 25, 26]. Two retrospective studies have reported that PpPD led to improved postoperative body weight changes, and provided a more favorable QOL compared with PD [7, 10]. On the other hand, several retrospective studies have reported that the postoperative body weight change and QOL did not significantly differ between PD and PpPD [6, 8, 9, 20–22]. Moreover, two RCTs also reported that body weight change and QOL did not exhibit significant differences between the two procedures [25, 26]. Seiler et al. [26] used the sickness impact profile (SIP), a standard questionnaire that assesses various physical, psychological, and social functions, to compare long-term QOL between PD and PpPD. They reported that the capacity to work at 6 months after surgery was better after PpPD (77%) than after PD (56%), although the postoperative QOL did not significantly differ between the two procedures [26]. Further studies should be performed to clarify the comparison

Table 1 Findings of randomized controlled trials comparing PD and PpPD

Authors	Years of study	Variable	Sample size	Pancreatic fistula (%)	DGE (%)	Mortality (%)	Median survival (months)
Lin et al. [23]	1994–1997	PD	15	0	38	7	NA
		PpPD	16	13	7	0	NA
Seiler et al. [24]	1996–1999	PD	49	2	45	5	NA
		PpPD	37	3	37	3	NA
Tran et al. [25]	1992–2000	PD	83	14	23	7	11.0
		PpPD	87	13	22	3	12.0
Seiler et al. [26]	1996–2001	PD	66	3	45	3	27.0
		PpPD	64	2	31	2	34.0
Lin et al. [27]	1994–2002	PD	19	5	0 ^a	11	12
		PpPD	14	7	43	7	33

PD pancreaticoduodenectomy, PpPD pylorus-preserving pancreaticoduodenectomy, DGE delayed gastric emptying, NA not available

^a $P < 0.05$